Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Therese Takas"'
Autor:
Vaishali S. Mankad, Amanda Leach, Yue Chang, Ulrika Wählby Hamrén, Alexandre Kiazand, Robert J. Kubiak, Therese Takas, Tonya Villafana, Manish Shroff
Publikováno v:
Pathogens, Vol 13, Iss 6, p 503 (2024)
Background: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to seve
Externí odkaz:
https://doaj.org/article/86743bdbdfea4b6889ccb3ced6d076df
Autor:
Magdalena E. Sobieszczyk, Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck Jr., Hong-Van Tieu, Kenneth H. Mayer, Lawrence Corey, Kathleen M. Neuzil, Tina Tong, Margaret Brewinski Isaacs, Holly Janes, Himanshu Bansal, Lindsay M. Edwards, Justin A. Green, Elizabeth J. Kelly, Kathryn Shoemaker, Therese Takas, Tom White, Prakash Bhuyan, Tonya Villafana, and Ian Hirsch, on behalf of the AstraZeneca AZD1222 Clinical Study Group
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 18 (2022)
Background We report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial.Methods Adults at increased risk of SARS-CoV-2 infection were randomized (2:1), stratified by age, to receive 2 doses of AZD1
Externí odkaz:
https://doaj.org/article/0223bfbe518d427787c488021708dfaa
Autor:
Eric A F Simões, Shabir A Madhi, William J Muller, Victoria Atanasova, Miroslava Bosheva, Fernando Cabañas, Manuel Baca Cots, Joseph B Domachowske, Maria L Garcia-Garcia, Ineta Grantina, Kim A Nguyen, Heather J Zar, Anna Berglind, Celeste Cummings, M Pamela Griffin, Therese Takas, Yuan Yuan, Ulrika Wählby Hamrén, Amanda Leach, Tonya Villafana
Publikováno v:
The Lancet Child & Adolescent Health. 7:180-189
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b36be4044817e1928b1acbaba4ff35dc
https://doi.org/10.1016/s2352-4642(22)00321-2
https://doi.org/10.1016/s2352-4642(22)00321-2
Autor:
Laura L, Hammitt, Ron, Dagan, Yuan, Yuan, Manuel, Baca Cots, Miroslava, Bosheva, Shabir A, Madhi, William J, Muller, Heather J, Zar, Dennis, Brooks, Amy, Grenham, Ulrika, Wählby Hamrén, Vaishali S, Mankad, Pin, Ren, Therese, Takas, Michael E, Abram, Amanda, Leach, M Pamela, Griffin, Tonya, Villafana, Jon, Heinrichs
Publikováno v:
New England Journal of Medicine. 386:837-846
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5c42be37ddafcb9c4a807fd65747198
https://doi.org/10.1056/nejmoa2110275
https://doi.org/10.1056/nejmoa2110275
Autor:
M Pamela, Griffin, Yuan, Yuan, Therese, Takas, Joseph B, Domachowske, Shabir A, Madhi, Paolo, Manzoni, Eric A F, Simões, Mark T, Esser, Anis A, Khan, Filip, Dubovsky, Tonya, Villafana, John P, DeVincenzo, Anne, Zomcik
Publikováno v:
New England Journal of Medicine. 383:415-425
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb3a24e11b71369dca5c0352090a83c2
https://doi.org/10.1056/nejmoa1913556
https://doi.org/10.1056/nejmoa1913556
Autor:
Ann R, Falsey, Magdalena E, Sobieszczyk, Ian, Hirsch, Stephanie, Sproule, Merlin L, Robb, Lawrence, Corey, Kathleen M, Neuzil, William, Hahn, Julie, Hunt, Mark J, Mulligan, Charlene, McEvoy, Edwin, DeJesus, Michael, Hassman, Susan J, Little, Barbara A, Pahud, Anna, Durbin, Paul, Pickrell, Eric S, Daar, Larry, Bush, Joel, Solis, Quito Osuna, Carr, Temitope, Oyedele, Susan, Buchbinder, Jessica, Cowden, Sergio L, Vargas, Alfredo, Guerreros Benavides, Robert, Call, Michael C, Keefer, Beth D, Kirkpatrick, John, Pullman, Tina, Tong, Margaret, Brewinski Isaacs, David, Benkeser, Holly E, Janes, Martha C, Nason, Justin A, Green, Elizabeth J, Kelly, Jill, Maaske, Nancy, Mueller, Kathryn, Shoemaker, Therese, Takas, Richard P, Marshall, Menelas N, Pangalos, Tonya, Villafana, Antonio, Gonzalez-Lopez, Barry S, Zingman
Publikováno v:
The New England Journal of Medicine
The New England journal of medicine, vol 385, iss 25
The New England journal of medicine, vol 385, iss 25
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd857161f6682ca59c79ec2e7fb130f
https://pubmed.ncbi.nlm.nih.gov/34587382
https://pubmed.ncbi.nlm.nih.gov/34587382
Autor:
Laura Hammitt, Ron Dagan, Yuan Yuan, Manuel Baca Cots, Miroslava Bosheva, Shabhir A Mahdi, William J Muller, Heather J Zar, Dennis Brooks, Amy Grenham, Ulrika Wählby Hamrén, Vaishali S Mankad, Pin Ren, Therese Takas, Jon Heinrichs, Amanda Leach, M Pamela Griffin, Tonya L Villafana
Publikováno v:
Open Forum Infectious Diseases
Background Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in infants. Nirsevimab is a single-dose monoclonal antibody with extended half-life that was shown to protect preterm infants 29 to < 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5de174c6dc7ce4e525e7d3c9e87fc4
http://europepmc.org/articles/PMC8644820
http://europepmc.org/articles/PMC8644820
Publikováno v:
Biologicals. 50:81-86
MEDI8852 is an IgG1 kappa monoclonal antibody that is being developed to treat patients hospitalized with influenza A. We evaluated the safety and tolerability, pharmacokinetics, and anti-drug antibodies (ADA) of a single intravenous dose of MEDI8852
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21e2d8b2232839a19a33980e8fec9cda
https://doi.org/10.1016/j.biologicals.2017.08.007
https://doi.org/10.1016/j.biologicals.2017.08.007
Autor:
S. Omar Ali, Nicole L. Kallewaard, Kathryn Shoemaker, Filip Dubovsky, Rafael Chiong, Raburn M. Mallory, Therese Takas, Andrew C. Nyborg
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
We evaluated MEDI8852, a human IgG1 monoclonal antibody that binds a highly conserved influenza A hemagglutinin stalk epitope, in outpatients with uncomplicated influenza A infection. A total of 126 subjects aged 18 to 65 years were enrolled during t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::194f679afce1a423df2a84ee3a44f065
https://doi.org/10.1128/aac.00694-18
https://doi.org/10.1128/aac.00694-18
Autor:
Joseph B. Domachowske, Filip Dubovsky, Therese Takas, M. Pamela Griffin, Kathryn Jensen, Anis A. Khan, Tonya Villafana, Mark T. Esser
Publikováno v:
The Pediatric infectious disease journal. 37(9)
MEDI8897 is a recombinant human monoclonal antibody being developed for prophylaxis of serious respiratory syncytial virus (RSV) disease in all infants.In this phase 1b/2a dose-escalation study, healthy preterm infants with a gestational age of 32-35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb95a01ad7d6a97850fcb1dc06ed925b
https://pubmed.ncbi.nlm.nih.gov/29373476
https://pubmed.ncbi.nlm.nih.gov/29373476